Epidemiology and Genomics Research Funding Opportunities

The Epidemiology and Genomics Research Program (EGRP) provides funding support for research in human populations to understand the causes of cancer and related outcomes. EGRP is the largest funder of cancer epidemiology grants nationally and worldwide. In addition to supporting investigator-initiated research grants, EGRP sponsors or co-sponsors a variety of targeted funding opportunity announcements (FOAs), and also is inviting participation in a prize competition. Here we provide a listing of funding opportunities that are currently accepting applications. Please visit this page regularly as new funding opportunities are added upon approval by NCI.


FOAs Sponsored/Co-Sponsored by EGRP

NOTE: The following table lists the newest FOAs at the top of the table.

FOAs Sponsored/Co-Sponsored
by EGRP
Announcement Number
(Grant Mechanism)
Submission Dates Expiration Date
Diet and Physical Activity Assessment Methodology
Summary Details
PAR-15-170External Web Site Policy (R01)
PAR-15-171External Web Site Policy (R21)

New R01 applications: Oct. 5, 2015; June 5, 2016; Feb. 5, 2017; Oct. 5, 2017; and June 5, 2018 (alternating standard R01 receipt dates)

R01 resubmission/renewal/revision applications: Nov. 5, 2015; July 5, 2016; Mar. 5, 2017; Nov. 5, 2017; and July 5, 2018 (alternating standard R01 receipt dates)

New R21 applications: Oct. 16, 2015; June 16, 2016; Feb. 16, 2017; Oct. 16, 2017; and June 16, 2018 (alternating standard due dates)

R21 resubmission applications: Nov. 16, 2015; July 16, 2016; Mar. 16, 2017; Nov. 16, 2017; and July 16, 2018 (alternating standard due dates)

Sept. 8, 2018

Summary:
These FOAs encourage innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under these FOAs are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. Several other NIH Institutes are also cosponsors of these FOAs. For more information: PAR-15-170External Web Site Policy (R01) and PAR-15-171External Web Site Policy (R21).

For diet assessment questions: Amy Subar, Ph.D., Program Director, Risk Factor Assessment Branch, e-mail: subara@mail.nih.gov

For physical activity assessment questions: Richard Troiano, Ph.D., Program Director, Risk Factor Assessment Branch, e-mail: troianor@mail.nih.gov

Early-life Factors and Cancer Development Later in Life
Summary Details
PA-15-124External Web Site Policy (R03)
PA-15-125External Web Site Policy (R21)
PA-15-126External Web Site Policy (R01)
Standard dates applyExternal Web Site Policy Jan. 8, 2018

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. In particular, this FOA supports research efforts that will help illuminate 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies. For more information: PA-15-124External Web Site Policy (R03), PA-15-125External Web Site Policy (R21), and PA-15-126External Web Site Policy (R01).

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Modifiable Risk Factors Branch; e-mail: mahabir@mail.nih.gov

Ethical, Legal, Social Implications of Human Genome Research
Summary Details
PA-14-276External Web Site Policy (R01) R01: Feb. 5, June 5, and Oct. 5 Sept. 8, 2017

Summary:
This PA invites multidisciplinary research applications that identify, examine, and address the ethical, legal, and social implications (ELSI) of advances in genomic research and technology for individuals, families, communities, and society more broadly. NCI is interested in empirical research that focuses on the ethical, legal, and social issues related to heritable cancer syndromes. Study of the psychosocial and behavioral impact on affected individuals, their families, and populations and research that takes into consideration the perpsectives of diverse racial, ethnic, and socioeconomic backgrounds, as well as children, older adults, and people with disabilities, is highly desirable. The ultimate goal of this research will be to improve outcomes related to the diagnosis of heritable cancer syndromes. The National Human Genome Research Institute (NHGRI) is the lead sponsor of the PA; several other NIH Institutes also are cosponsors. For more information: PA-14-276External Web Site Policy (R01).

Contact: Charlisse Caga-anan, J.D., Program Director, Genomic Epidemiology Branch, e-mail: cagaananef@mail.nih.gov

Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection
Summary Details
PAR-14-254External Web Site Policy (R21)
PAR-14-255External Web Site Policy (R01)
Standard AIDS dates applyExternal Web Site Policy May 8, 2017

Summary:
The purpose of these FOAs is to fill gaps in the understanding of the pathogenic interactions between HIV and hepatitis viruses, co-morbidities associated with HIV/hepatitis virus co-infection, and the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV/HCV co-infection. For more information: PAR-14-254External Web Site Policy (R21) and PAR-14-255External Web Site Policy (R01).

Contact: Vaurice Starks, Program Director, Methods and Technologies Branch, e-mail: starksv@mail.nih.gov

Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts
Summary Details
PAR-15-104External Web Site Policy (U01) Apr. 1, July 8, and Nov. 10, 2015
Mar. 11, July 8, and Nov. 10, 2016
Mar. 10, 2017
Mar. 11, 2017

Summary:
This PAR invites grant applications to provide targeted infrastructure support for the core functions of cancer epidemiology cohorts (CECs) and methodological research. This infrastructure can support existing or new CECs. This PAR will support core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genomics Research Program (EGRP) and other components of NCI’s Division of Cancer Control and Population Sciences (DCCPS). For more information: PAR-15-104External Web Site Policy (U01) and FAQs

Contact: Joanne Elena, Ph.D., M.P.H., Program Director, Clinical and Translational Epidemiology Branch, e-mail: elenajw@mail.nih.gov

Genomic Resource Grants for Community Resource Projects
Summary Details
PAR-14-191External Web Site Policy (U41) Jan. 25, May 25, and Sept. 25, 2015
Jan. 25, May 25, and Sept. 25, 2016
Jan. 25, 2017
Jan. 26, 2017

Summary:
Awards under this FOA will support the development and distribution of genomic resources that will be available to and valuable for the broad research community, using cost-effective approaches. Such resources include (but are not limited to) informatics resources (such as human and model organism databases, ontologies, and coordinated sets of analysis tools), comprehensive identification and collections of genomic features (such as structural variants or functional genomic elements), and standard data types produced for central sets of samples (such as 1000 Genomes or GTEx samples). The National Human Genome Research Institute (NHGRI) is the lead sponsor of the FOA and NCI is a co-sponsor. For more information: PAR-14-191External Web Site Policy (U41).

Contact:: Leah Mechanic, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, e-mail: mechanil@mail.nih.gov

Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment
Summary Details
PAR-15-075External Web Site Policy (R01) Mar. 6, 2015
Thereafter, standard dates apply.
Jan. 8, 2017

Summary:
This FOA encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of technologies, methods, assays, devices, and/or systems that are designed to solve a targeted cancer problem. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following: current commercially supported systems, next-generation systems, quality assurance and quality control, validation and correlation studies, quantitative imaging, and related research resources. Applications should be translational in scope; therefore, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. Innovation may be considered as delivery of a new capability to end users. Applications should establish the academic-industrial partnership as an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their system to solve their chosen cancer problem. For more information: PAR-15-075External Web Site Policy (R01).

Contact:: Rao L. Divi, Ph.D., Program Director, Methods and Technologies Branch, e-mail: divir@mail.nih.gov

Research on Malignancies in the Context of HIV/AIDS
Summary Details
PAR-13-377External Web Site Policy (R01); see also PAR-13-378External Web Site Policy (R21) R01: Jan. 7, May 7, and Sept. 7
R21: Jan. 7, May 7, and Sept. 7
Sept. 8, 2016

Summary:
The purpose of these PAs is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS). These PAs seek to encourage research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both AIDS-defining and non-AIDS-defining malignancies in diverse populations.

These PAs invite research efforts that will: (1) provide information on the clinical outcomes of such cancers in the HIV-infected population; and (2) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers. Office of AIDS Malignancy Program, with the National Institute of Dental and Craniofacial Research (NIDCR). For more information: PAR-13-377External Web Site Policy (R01); PAR-13-378External Web Site Policy (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov; and Vaurice Starks, Program Director, Methods and Technologies Branch, e-mail: starksv@mail.nih.gov

Mechanistic Insights from Birth Cohorts
Summary Details
PAR-13-109External Web Site Policy (R01); see also NOT-CA-13-002External Web Site Policy June 5, Oct. 5, 2013
Feb. 5, June 5, Oct. 5, 2014
Feb. 5, June 5, Oct. 5, 2015
Feb. 5, 2016
May 8, 2016

Summary:
This FOA is intended to support novel research on how prenatal exposures contribute to the etiology of chronic diseases and health conditions later in life. Little is known about the mechanisms by which such prenatal exposures lead to diabetes or obesity, renal, pulmonary, or cardiovascular or hematologic disease, neurodevelopmental disorders, reproductive health (i.e. fertility), or cancer. The goal of this FOA is to stimulate research by leveraging existing birth cohorts to address targeted mechanistic questions regarding the normal and abnormal developmental origins of organ systems and/or diseases of interest to the participating NIH Institutes and Centers. For more information: PAR-13-109External Web Site Policy and NOT-CA-13-002External Web Site Policy.

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: mahabir@mail.nih.gov

Obesity Policy Evaluation Research
Summary Details
PAR-13-110External Web Site Policy (R01) Standard dates applyExternal Web Site Policy May 8, 2016

Summary:
This FOA encourages applications that propose to evaluate large scale policy or programs that are expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. For more information: PA-13-110External Web Site Policy (R01).

Contact: Robin A. McKinnon, Ph.D., M.P.A., Program Director, Risk Factor Assessment Branch, e-mail: mckinnonr@mail.nih.gov

Time Sensitive Obesity Policy and Program Evaluation
Summary Details
PAR-12-257External Web Site Policy (R01) Mar. 10, Apr. 14, May 11, June 10, July 10, Aug. 12, and Sept. 10, 2015 Sept. 11, 2015

Summary:
This FOA establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. Several other NIH Institutes are also cosponsors of this FOA. For more information: PAR-12-257External Web Site Policy (R01).

Contact: Robin A. McKinnon, Ph.D., M.P.A., Program Director, Risk Factor Assessment Branch, e-mail: mckinnonr@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-286External Web Site Policy (R01, R37) R01 and R37:
Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR encourages revision applications (formerly called "competing revisions") from currently funded R01s and R37s with at least one year left at the estimated time of award. Early-stage development is defined as the initial development or significant modification of existing tools for new applications. For more information: PAR-12-286External Web Site Policy (R01, R37)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Advanced Development of Informatics Technology
Summary Details
PAR-12-287External Web Site Policy (U24) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites U24s for advanced development and enhancement of emerging informatics technologies, which are ones that have passed the initial prototyping and pilot development stage, demonstrated potential to have a significant and broader impact, have compelling reasons for further improvement and enhancement, and have not been widely adopted in the cancer research field. For more information: PAR-12-287External Web Site Policy (U24)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Early-Stage Development of Informatics Technology
Summary Details
PAR-12-288External Web Site Policy (U01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites U01s and focuses on early-stage development from prototyping to hardening and adaption. For more information: PAR-12-288External Web Site Policy (U01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-289External Web Site Policy (U01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR solicits revisions (formerly called "competing revisions") from currently funded U01s with at least one year left at the estimated time of award. For more information: PAR-12-289External Web Site Policy (U01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-290External Web Site Policy (P01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites revisions (formerly called "competing revisions") from currently funded P01s with at least one year left at the estimated time of award. For more information: PAR-12-290External Web Site Policy (P01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov


Other funding opportunities of interest not sponsored by EGRP


EGRP-sponsored Prize Competition

Challenge and prize competitions are one path that federal agencies take to drive innovation and solve mission-centric problems — whether technical, scientific, or creative.

EGRP is partnering with SAGE Bionetworks to launch "Up for a Challenge (U4C)—Stimulating Innovation in Breast Cancer Genetic Epidemiology" to encourage innovative approaches to more fully explain the genomic basis of breast cancer. Up to $50,000 in prizes will be awarded based on the identification of novel findings, replication of findings, innovation of approach, evidence of novel biological hypotheses, and collaboration.

In order to complete the Challenge, participants will have access to genetic epidemiologic data from thousands of breast cancer cases and controls from ethnically diverse populations. Some of these data sets are being made available for researchers for the first time for this challenge. Note: U4C participants will need to request data access through NIH's Database of Genotypes and Phenotypes (dbGaP)External Web Site Policy. Learn more about the data access request process.

For more information, visit the U4C websiteExternal Web Site Policy for more information about the U4C application, due dates, rules, and other FAQs.



Stay Up to Date

Subscribe to EGRP's monthly Cancer Epidemiology E-News to receive details about recent NIH FOAs and Notices of Intent to publish an FOA, as well as relevant funding opportunities from other organizations.

Return to Top